The Top 5 Biosimilars Articles for the Week of August 12
The Center for Biosimilars® recaps the top stories for the week of August 12, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 12, 2019.
Number 5: Being presented with positively framed information on biosimilars is linked with greater willingness to accept a switch, says a recent study.
Number 4: New data from a phase 3 study in patients with rheumatoid arthritis show that Fresenius Kabi’s biosimilar adalimumab has similar safety to Humira.
Number 3: A retrospective analysis of prescription claims shows the importance of an oncology specialty pharmacy team in ensuring access to financial assistance.
Number 2: Authors of a new paper say it’s time to replace the totality of the evidence approach to biosimilars with a new paradigm.
Number 1: A judge ruled in favor of Amgen in a long-running patent litigation concerning Sandoz’s biosimilar etanercept, Erelzi.
Finally, last week, our e-newsletter asked whether you think that Celltrion’s proposed subcutaneous infliximab biosimilar could compete with brand-name adalimumab.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
